JP2001514000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001514000A5 JP2001514000A5 JP2000507804A JP2000507804A JP2001514000A5 JP 2001514000 A5 JP2001514000 A5 JP 2001514000A5 JP 2000507804 A JP2000507804 A JP 2000507804A JP 2000507804 A JP2000507804 A JP 2000507804A JP 2001514000 A5 JP2001514000 A5 JP 2001514000A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- domain
- cell
- eliciting
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 6
- 241000186366 Mycobacterium bovis Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 241000186359 Mycobacterium Species 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 1
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97114614.7 | 1997-08-22 | ||
| EP97114614A EP0902086A1 (en) | 1997-08-22 | 1997-08-22 | Tuberculosis vaccine |
| PCT/EP1998/005109 WO1999010496A1 (en) | 1997-08-22 | 1998-08-12 | Tuberculosis vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001514000A JP2001514000A (ja) | 2001-09-11 |
| JP2001514000A5 true JP2001514000A5 (enExample) | 2006-01-05 |
| JP4255209B2 JP4255209B2 (ja) | 2009-04-15 |
Family
ID=8227261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000507804A Expired - Lifetime JP4255209B2 (ja) | 1997-08-22 | 1998-08-12 | 結核ワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6673353B1 (enExample) |
| EP (2) | EP0902086A1 (enExample) |
| JP (1) | JP4255209B2 (enExample) |
| AT (1) | ATE347599T1 (enExample) |
| AU (1) | AU9435098A (enExample) |
| CA (1) | CA2301879C (enExample) |
| CY (1) | CY1106350T1 (enExample) |
| DE (1) | DE69836588T2 (enExample) |
| DK (1) | DK1007686T3 (enExample) |
| ES (1) | ES2274580T3 (enExample) |
| PT (1) | PT1007686E (enExample) |
| SI (1) | SI1007686T1 (enExample) |
| WO (1) | WO1999010496A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
| US7820180B2 (en) * | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
| US8956621B2 (en) | 1994-11-08 | 2015-02-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
| US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
| US7794729B2 (en) | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
| US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| US7662396B2 (en) | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
| DK1144447T3 (da) * | 1998-11-04 | 2010-02-08 | Isis Innovation | Dianostisk tuberkulosetest |
| GB0006693D0 (en) * | 2000-03-20 | 2000-05-10 | Glaxo Group Ltd | Vaccine |
| US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
| AU2001255196A1 (en) | 2000-03-29 | 2001-10-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
| US7700344B2 (en) | 2001-03-26 | 2010-04-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
| US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| MXPA05008342A (es) * | 2003-02-06 | 2006-02-28 | Cerus Corp | Listeria atenuada para la entrada a las celulas no fagociticas, vacunas que comprenden la listeria, y metodos de uso de las mismas. |
| SI1618128T1 (sl) | 2003-04-23 | 2010-11-30 | Max Planck Gesellschaft | Cepivo proti tuberkolozi z izboljšano učinkovitostjo |
| EP1649869A1 (en) * | 2004-10-21 | 2006-04-26 | Vakzine Projekt Management GmbH | Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
| EA012434B1 (ru) | 2004-12-01 | 2009-10-30 | ЭЙРАС ГЛОУБАЛ ТиБи ВЭКСИН ФАУНДЕЙШН | Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы |
| US8268326B2 (en) | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
| DK2977456T3 (en) | 2006-08-15 | 2018-01-22 | Univ Pennsylvania | Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer |
| US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
| US20110129499A1 (en) | 2008-05-19 | 2011-06-02 | Paulo Maciag | Dual delivery system for heterologous antigens |
| US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
| US8778329B2 (en) | 2009-03-04 | 2014-07-15 | The Trustees Of The University Of Pennsylvania | Compositions comprising angiogenic factors and methods of use thereof |
| US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
| KR101907222B1 (ko) | 2010-09-20 | 2018-10-11 | 바크지네 프로제크트 마나게멘트 게엠베하 | 인간에게 사용하기 위한 백신으로서 재조합 마이코박테리움 |
| WO2012138377A2 (en) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| JP6055780B2 (ja) | 2010-12-21 | 2016-12-27 | マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． | 抗マイコバクテリアのワクチン接種の有効性の判定 |
| LT2654783T (lt) * | 2010-12-21 | 2016-11-25 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rekombinantinė mikobakterija kaip vakcina |
| WO2012125551A1 (en) | 2011-03-11 | 2012-09-20 | Advaxis | Listeria-based adjuvants |
| BR102012003790A2 (pt) | 2012-02-17 | 2014-04-22 | Fundacao Butantan | Cepa de mycobacterium recombinante, composição imunogênica e uso |
| SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
| WO2013151731A1 (en) * | 2012-04-02 | 2013-10-10 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium for induction of cellular immune response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504005A (en) * | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
-
1997
- 1997-08-22 EP EP97114614A patent/EP0902086A1/en not_active Withdrawn
-
1998
- 1998-08-12 PT PT98947427T patent/PT1007686E/pt unknown
- 1998-08-12 WO PCT/EP1998/005109 patent/WO1999010496A1/en not_active Ceased
- 1998-08-12 US US09/485,717 patent/US6673353B1/en not_active Expired - Lifetime
- 1998-08-12 AT AT98947427T patent/ATE347599T1/de active
- 1998-08-12 DK DK98947427T patent/DK1007686T3/da active
- 1998-08-12 DE DE69836588T patent/DE69836588T2/de not_active Expired - Lifetime
- 1998-08-12 JP JP2000507804A patent/JP4255209B2/ja not_active Expired - Lifetime
- 1998-08-12 CA CA2301879A patent/CA2301879C/en not_active Expired - Lifetime
- 1998-08-12 ES ES98947427T patent/ES2274580T3/es not_active Expired - Lifetime
- 1998-08-12 AU AU94350/98A patent/AU9435098A/en not_active Abandoned
- 1998-08-12 SI SI9830871T patent/SI1007686T1/sl unknown
- 1998-08-12 EP EP98947427A patent/EP1007686B1/en not_active Expired - Lifetime
-
2007
- 2007-03-01 CY CY20071100297T patent/CY1106350T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001514000A5 (enExample) | ||
| JP3485916B2 (ja) | 組み換えマイコバクテリアの発現ベヒクルおよびその使用 | |
| EP1303299B1 (en) | Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens | |
| Stover et al. | New use of BCG for recombinant vaccines | |
| US5591632A (en) | Recombinant BCG | |
| US6855320B2 (en) | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity | |
| CA2523084A1 (en) | Tuberculosis vaccine with improved efficacy | |
| Crocquet-Valdes et al. | Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis | |
| US20130149324A1 (en) | Therapeutic tb vaccine | |
| AU2010238943A1 (en) | A tuberculosis TB vaccine to prevent reactivation | |
| US20060140975A1 (en) | Regulated bacterial lysis for gene vaccine vector delivery and antigen release | |
| Zhu et al. | Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection | |
| EP0804230B1 (en) | Vaccine against mycobacterial infections | |
| Brockstedt et al. | Promises and challenges for the development of Listeria monocytogenes-based immunotherapies | |
| JP2003510018A5 (enExample) | ||
| Armengol et al. | The injection of plasmid DNA in mouse muscle results in lifelong persistence of DNA, gene expression, and humoral response | |
| TWI221847B (en) | Clostridium perfringens vaccine | |
| Abomoelak et al. | Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guerin producing a pertussis toxin-tetanus toxin hybrid protein | |
| Skeiky et al. | Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41 | |
| Deng et al. | Improved Immunogenicity of Recombinant Mycobacterium bovis Bacillus Calmette‐Guérin Strains Expressing Fusion Protein Ag85A‐ESAT‐6 of Mycobacterium tuberculosis | |
| FUERST et al. | Development and analysis of recombinant BCG vector systems | |
| Campbell et al. | Bacterial surface proteins recognized by CD4+ T cells during murine infection with Listeria monocytogenes | |
| Faludi et al. | Recombinant Mycobacterium smegmatis vaccine candidates | |
| WO2006053485A1 (fr) | Vaccin genique contre le bacille mycobacterium tuberculosis obtenu a partir d’un gene chimere et procede de preparation dudit vaccin | |
| US8299232B2 (en) | Constructing a DNA chimera for vaccine development against leishmaniasis and tuberculosis |